Printer Friendly

First Patient Dosed in Merrimack Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer.

M2 PHARMA-March 1, 2018-First Patient Dosed in Merrimack Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer

(C)2018 M2 COMMUNICATIONS

- Cambridge, Massachusetts-based cancer therapeutics developer Merrimack Pharmaceuticals (NASDAQ: MACK) has dosed the first patient in its SHERBOC study, a double-blind, placebo-controlled randomized Phase 2 clinical trial of MM-121 (seribantumab) in patients with heregulin-positive, hormone receptor-positive and HER2-negative post-menopausal metastatic breast cancer, the company said.

MM-121, also known as seribantumab, is a fully human monoclonal antibody that targets HER3 signaling and is designed to overcome cancer cells' resistance to the effects of anti-tumor therapies.

The global, multi-site, randomized Phase 2 study will assess progression-free survival of MM-121, in combination with fulvestrant, versus a placebo and fulvestrant. The study will enroll heregulin-positive, hormone receptor-positive and HER2-negative post-menopausal breast cancer patients who have progressed after one or two lines of prior systemic therapies for metastatic or locally advanced disease and have received prior CDK inhibitor-based therapy.

The first patient in the SHERBOC study was dosed at the UF Health Cancer Center at Orlando Health in the United States.

Merrimack's mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.

All of Merrimack's development programmes, including four clinical studies and six candidates in preclinical development, fit into its strategy of understanding the biological problems it is trying to solve, designing specific solutions, and developing those solutions for biomarker-selected patients.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Clinical report
Date:Mar 1, 2018
Words:257
Previous Article:Genomic Health Launches Liquid Biopsy Test to Predict Treatment Response in Metastatic Castration-resistant Prostate Cancer.
Next Article:Check-Cap Names Alex Ovadia as CEO.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters